Melatech Due Diligence

Run due diligence on Melatech: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Independent (Denmark) · melatech.io · 13 vendors

Melatech is a Danish company that empowers primary care clinicians with an AI-enhanced hardware and software platform. The platform enables clinicians to capture clinical data, collaborate with specialists, and convert consultations into structured documentation. Its goal is to reduce administrative burden and free up more time for direct patient care.

Resilience scores

Technology vendors

Insights

Last updated 2026-11-22 · revision 8

13 direct vendors, 156 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

10 in-scope frameworks identified; showing 3.

EU MDR — Evidence found

Melatech's products, which include software and hardware for clinical documentation and communication, fall under the definition of medical devices and are therefore subject to the EU Medical Device Regulation.

Evidence: https://docs.melatech.io/en/products/seranote/data-protection/, https://trust.melatech.io/, https://tracxn.com/d/companies/melatech/__9xaYC38s7OjK7M6-hY5B9mdmb6KsC5Ycg3NeSPZtbaQ, https://accelerace.io/melatech-democratising-cancer-diagnosis/, https://digital.nemko.com/regulations/medical-devices-regulation, https://pitchbook.com/profiles/company/517822-03

EU AI Act (source) — No public evidence

Melatech develops an "AI-enhanced Hardware and Software Platform" for primary care. As its products incorporate artificial intelligence and are regulated as medical devices, they will be classified as high-risk AI systems under the EU AI Act.

ISO 13485 — No public evidence

As a manufacturer of medical devices (including software) for the EU market, implementing a quality management system compliant with ISO 13485 is the standard industry practice to meet regulatory requirements under the EU MDR.

Financials

Three-year financials

Financial Resilience Score: 5/10

Melatech shows a mixed resilience profile typical of an early-stage healthtech company. On the positive side, gross profit has grown roughly 10x over two years (DKK 0.86M to DKK 8.83M), headcount nearly tripled, and the company has secured repeated equity injections (share capital raised from DKK 40K in 2021 to DKK 1.04M in October 2026) alongside non-dilutive public funding including a DKK 3.93M Grand Solutions grant (2023) and DKK 1.54M Innobooster grant (2026-2028). Governance has strengthened with auditor upgrades from a small local firm to BDO and then Deloitte, plus new board chair and director appointments in 2026. On the risk side, the company has posted sustained net losses of DKK 2.5-3.1M annually across 2023-2025, consuming equity which dropped from DKK 7.33M to DKK 4.84M in 2025 alone. At current burn rate, remaining equity covers under two years without a new round. Personnel costs nearly doubled from DKK 5.9M (2024) to DKK 11.0M (2025), creating operating leverage risk if gross profit growth stalls. Revenue is not disclosed, obscuring unit economics. Total external funding is modest ($0.6M-$1.8M per external sources), and shareholder turnover suggests ongoing cap-table restructuring. Overall resilience is moderate - adequate for near-term operations but dependent on continued investor support.

Key strengths: Gross profit grew ~10x from DKK 0.86M (2023) to DKK 8.83M (2025), Repeated equity injections; share capital raised to DKK 1.04M by Oct 2026, Non-dilutive public grants: DKK 3.93M Grand Solutions (2023) and DKK 1.54M Innobooster (2026-2028), Auditor upgrade progression: local firm -> BDO -> Deloitte, Governance strengthening with new chair and director in 2026, Headcount scaled from 8 (2023) to 19 average (2025), 21 registered

Risk factors: Sustained net losses of DKK 2.5-3.1M per year across 2023-2025, Equity dropped from DKK 7.33M to DKK 4.84M in 2025; under 2 years of runway at current burn, Personnel costs nearly doubled from DKK 5.9M to DKK 11.0M in 2025, Revenue not disclosed - opaque unit economics, Modest total external funding ($0.6M-$1.8M), Shareholder turnover indicating ongoing cap-table restructuring, Small, concentrated startup competing internationally

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report